source
- Swiss startup Vaderis raises $152 million to fund Phase 3 trial of rare bleeding disorder therapyVaderis Therapeutics, a 13‑person Swiss biotech, announced a $152 million Series B financing round aimed at advancing its experimental therapy into a Phase 3 study. The company is testing a treatm…
- Vaderis raises $152 million to launch late-stage trials of AKT inhibitor engasertib for rare bleeding disorderVaderis Therapeutics announced a $152 million Series B financing round, giving it sufficient capital to advance its experimental AKT-targeting drug, engasertib. The company has also begun late-sta…